Stay Connected

Request an AQNEURSA Representative

Contact Preference

How would you like to be contacted initially?*
Are you currently managing patients with Ataxia-Telangiectasia?*
Do you currently have patients taking AQNEURSA?*

Confirmations & Consent

I confirm I am a healthcare professional in the US.*
Please accept our policy.*
By completing and submitting this form, you agree to allow IntraBio and its agents to collect the information provided and to be contacted by IntraBio and its agents in the future regarding products and related disease education. IntraBio will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of IntraBio and its agents. IntraBio will only use your information in accordance with its Privacy Policy.
Important Safety Information
Before taking AQNEURSA, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
  • Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy.
  • Your healthcare provider will check to make sure you are not pregnant before starting treatment with AQNEURSA.
  • Use effective birth control (contraception) during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
  • If you become pregnant while taking AQNEURSA, inform your healthcare provider immediately to discuss potential risks and alternative treatments.
  • It is not known if AQNEURSA or its metabolites pass into human or animal milk or effect breastmilk production.
Tell your healthcare provider about all the medications you take and if you get any new medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may cause side effects or affect how AQNEURSA works when used together.
  • Tell your healthcare provider if you are taking certain medications called P-gp substrates, N-acetyl-DL-leucine or N-acetyl-D-leucine. If you are not sure if you are taking these medicines, talk to your healthcare provider or pharmacist.
The most common side effects of AQNEURSA in people treated for ataxia-telangiectasia include fall, skin laceration, and urinary tract infection.

These are not all the possible side effects of AQNEURSA. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

References:
1. AQNEURSA. Prescribing information. IntraBio.
2. Martakis K, et al. Lancet Neurol. 2026 Jul;25(7):633-644.
3. Crawford TO. Semin Pediatr Neurol. 1998;5(4):287-294.
4. Rothblum-Oviatt C, et al. Orphanet J Rare Dis. 2016;11(1):159.
Back to top
Logo for IntraBio, a late-stage biopharmaceutical company focused on therapies for neurodegenerative diseases with high unmet medical needs

This site is intended for US residents only.

AQNEURSA, AQNEURSA Cares, and their respective logos are trademarks of IntraBio.

© 2026 IntraBio. All rights reserved. MAT-0219 09/26

Austin, TX

Contact Us
Privacy Policy
Cookie Policy

Important Safety Information

Before taking AQNEURSA, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
  • Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy.
  • Your healthcare provider will check to make sure you are not pregnant before starting treatment with AQNEURSA.
  • Use effective birth control (contraception) during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
  • If you become pregnant while taking AQNEURSA, inform your healthcare provider immediately to discuss potential risks and alternative treatments.
  • It is not known if AQNEURSA or its metabolites pass into human or animal milk or effect breastmilk production.
Tell your healthcare provider about all the medications you take and if you get any new medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may cause side effects or affect how AQNEURSA works when used together.
  • Tell your healthcare provider if you are taking certain medications called P-gp substrates, N-acetyl-DL-leucine or N-acetyl-D-leucine. If you are not sure if you are taking these medicines, talk to your healthcare provider or pharmacist.

The most common side effects of AQNEURSA in people treated for ataxia-telangiectasia include fall, skin laceration, and urinary tract infection.

These are not all the possible side effects of AQNEURSA. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

AQNEURSA® (levacetylleucine) is indicated for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg.

Please click here for Full Prescribing Information for AQNEURSA.